Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer Protein

Cat. No. MHC-HM107



Description	
Source	Recombinant Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer Protein is expressed from HEK293 with His tag at the C-terminus.
	It contains Gly25-Thr206 (Human HLA-A*02:01 α 1& α 2) and Asp207-Glu299 (Mouse H-2Ld α 3), Ile21-Met119 (mB2M) and ILAKFLHWL peptide.
Accession	A0A140T913(Human HLA-A*02:01 α1&α2)&P01897(Mouse H-2Ld α3)&&P01887(Mouse B2M)&ILAKFLHWL
Molecular Weight	The protein has a predicted MW of 48.00 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation Supplied as 0.22 µm filtered solution in PBS (pH 7.4).


Storage Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The human telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) is expressed in many human cancer cells derived from multiple tissues, but infrequently in normal cells. Thus, hTERT is an attractive candidate target for tumor immunotherapy. hTERT:540–548 peptide (p540, ILAKFLHWL) has been identified as an effective HLA-A*0201-restricted T-cell epitope, an effective T-cell-based cancer treatment, including vaccines, against hTERT will likely require the identification of other MHC class I-restricted epitopes in this antigen.

Assay Data

Bis-Tris PAGE



Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


SEC-HPLC

Chimeric HLA-A*02:01 (mα3) &mB2M&TERT (ILAKFLHWL) Monomer Protein

Cat. No. MHC-HM107



Assay Data



The purity of Chimeric HLA-A*02:01 (m α 3) &mB2M&TERT (ILAKFLHWL) Monomer is greater than 95% as determined by SEC-HPLC.